These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 7767393)

  • 1. Multicentre trial of antepartum low-dose anti-D immunoglobulin.
    Lee D; Rawlinson VI
    Transfus Med; 1995 Mar; 5(1):15-9. PubMed ID: 7767393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of Rh alloimmunization.
    Fung Kee Fung K; Eason E; Crane J; Armson A; De La Ronde S; Farine D; Keenan-Lindsay L; Leduc L; Reid GJ; Aerde JV; Wilson RD; Davies G; Désilets VA; Summers A; Wyatt P; Young DC;
    J Obstet Gynaecol Can; 2003 Sep; 25(9):765-73. PubMed ID: 12970812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The scientific basis of antenatal prophylaxis.
    Urbaniak SJ
    Br J Obstet Gynaecol; 1998 Nov; 105 Suppl 18():11-8. PubMed ID: 9863973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Guideline for prevention of RhD alloimmunizationin RhD negative women].
    Lubušký M; Procházka M; Simetka O; Holusková I
    Ceska Gynekol; 2013 Apr; 78(2):132-3. PubMed ID: 23710977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intramuscular versus intravenous anti-D for preventing Rhesus alloimmunization during pregnancy.
    Okwundu CI; Afolabi BB
    Cochrane Database Syst Rev; 2013 Jan; (1):CD007885. PubMed ID: 23440818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Spontaneous antepartal RhD alloimmunization].
    Studničková M; Holusková I; Durdová V; Kratochvílová T; Strašilová P; Marková I; Lubušký M
    Ceska Gynekol; 2015 Dec; 80(6):401-4. PubMed ID: 26741153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Following targeted routine antenatal anti-D prophylaxis, almost half of the pregnant women had undetectable anti-D prophylaxis at delivery.
    Sørensen K; Stjern HE; Karlsen BAG; Tomter G; Ystad I; Herud I; Baevre MS; Llohn AH; Akkök ÇA
    Acta Obstet Gynecol Scand; 2022 Apr; 101(4):431-440. PubMed ID: 35224728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-D administration after spontaneous miscarriage for preventing Rhesus alloimmunisation.
    Karanth L; Jaafar SH; Kanagasabai S; Nair NS; Barua A
    Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD009617. PubMed ID: 23543581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-D administration in pregnancy for preventing rhesus alloimmunisation.
    Crowther CA; Keirse MJ
    Cochrane Database Syst Rev; 2000; (2):CD000020. PubMed ID: 10796088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antenatal prophylaxis of Rh immunization with 250 micrograms anti-D immunoglobulin.
    Hermann M; Kjellman H; Ljunggren C
    Acta Obstet Gynecol Scand Suppl; 1984; 124():1-15. PubMed ID: 6095582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripartum factors predicting the need for increased doses of postpartum rhesus immune globulin.
    Leyenaar L; Allen VM; Robinson HE; Parsons M; Van den Hof MC
    J Obstet Gynaecol Can; 2010 Aug; 32(8):739-44. PubMed ID: 21050504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Guideline for prevention of RhD alloimmunization in RhD negative women].
    Lubuský M; Procházka M; Simetka O; Holusková I
    Ceska Gynekol; 2010 Aug; 75(4):323-4. PubMed ID: 20925231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prevention of Rh (D) alloimmunization in Rh (D) negative women in pregnancy and after birth of Rh (D) positive infant].
    L'ubuský M; Procházka M; Krejcová L; Vetr M; Santavý J; Kudela M
    Ceska Gynekol; 2006 May; 71(3):173-9. PubMed ID: 16768042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of RhD alloimmunization in RhD negative women.
    Lubusky M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2010 Mar; 154(1):3-7. PubMed ID: 20445704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Routine antenatal anti-D prophylaxis and patient compliance with the two-dose regimen.
    Chaffe B; Ford J; Bills V
    Transfus Med; 2007 Oct; 17(5):399-403. PubMed ID: 17903141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Costs and benefits of non-invasive fetal RhD determination.
    Teitelbaum L; Metcalfe A; Clarke G; Parboosingh JS; Wilson RD; Johnson JM
    Ultrasound Obstet Gynecol; 2015 Jan; 45(1):84-8. PubMed ID: 25380024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rhesus D factor (RhD) negative women's experiences with pregnancy: An interpretive description.
    Fyfe TM; Lavoie JG; Payne GW; Banner D
    Women Birth; 2020 Nov; 33(6):e511-e518. PubMed ID: 32035799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The economics of routine antenatal anti-D prophylaxis for pregnant women who are rhesus negative.
    Chilcott J; Tappenden P; Lloyd Jones M; Wight J; Forman K; Wray J; Beverley C
    BJOG; 2004 Sep; 111(9):903-7. PubMed ID: 15327602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Costs and clinical outcomes of noninvasive fetal RhD typing for targeted prophylaxis.
    Hawk AF; Chang EY; Shields SM; Simpson KN
    Obstet Gynecol; 2013 Sep; 122(3):579-85. PubMed ID: 23921866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for RhD immunisation despite antenatal and postnatal anti-D prophylaxis.
    Koelewijn JM; de Haas M; Vrijkotte TG; van der Schoot CE; Bonsel GJ
    BJOG; 2009 Sep; 116(10):1307-14. PubMed ID: 19538414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.